排序方式： 共有34条查询结果，搜索用时 15 毫秒
1.
A 4-month old, 200 kg, grey warmblood colt presented for a firm, non painful mass on the distal medial aspect of the left third metatarsus. Excisional biopsy revealed a diagnosis of haemangiosarcoma. Equine haemangiosarcoma is uncommon and only limited reports of successful treatment are available. The prognosis for survival is therefore considered to be poor. After two separate incidences of recurrence with incomplete excision of the tumour, intralesional treatment with cisplatin without excision or debulking was performed on three separate occasions. Intralesional cisplatin injection was performed at monthly intervals for three treatments. Four years post treatment with cisplatin, the horse remained in remission. This case report describes the diagnostic and treatment challenges for successful treatment of a primary haemangiosarcoma on the distal limb of a warmblood foal using intralesional cisplatin chemotherapy. 相似文献
2.
Tamzali Y Borde L Rols MP Golzio M Lyazrhi F Teissie J 《Equine veterinary journal》2012,44(2):214-220
Reasons for performing study: Sarcoids are the commonest form of equine skin tumour. Several therapeutic measures have been described but none is considered to be universally effective. Electrochemotherapy (ECT) is a new anticancer therapy that utilises electrical field pulses to induce increased cell membrane permeability to antitumour hydrophilic drugs, such as cisplatin. The increased intracellular concentration of the drugs has a significant therapeutic benefit. The procedure has not been previously reported in a large number of horses. Objective: To validate ECT as a novel alternative treatment for equine sarcoids. Methods: A retrospective study evaluating the efficacy of cisplatin ECT in the treatment of equine sarcoids was performed. Electrochemotherapy treatments were applied under general anaesthesia at 2 week intervals with or without prior excision or debulking. Electric pulses were directly applied to the lesions following intra‐tumoural injections of an aqueous solution of cisplatin. Results: One‐hundred‐and‐ninety‐four sarcoids on 34 horses, 2 ponies, 11 donkeys and one mule were treated with ECT. The 4 year nonrecurrence rate was 97.9% for animals (47/48) and 99.5% (193/194) for tumours. When ECT was used as a single treatment, a significant influence of tumour size (ρ= 0.55) on the number of treatments required for cure was shown. When prior surgery was performed, there was a significant influence (P<0.001) of the excision quality (complete or incomplete) and the healing mode (closed or open wound) on the number of treatments. The most common adverse effect was a slight oedematous reaction for lesions located on thin skin regions. Conclusion and clinical relevance: Results demonstrate that ECT, with or without concurrent tumour debulking, is an effective alternative for treatment of equine sarcoids. 相似文献
3.
Cisplatin is a platinum chemotherapeutic used in a variety of malignancies. The antineoplastic activity occurs from DNA cross‐links and adducts, in addition to the generation of superoxide radicals. Nephrotoxicity is the most well‐known and potentially most clinically significant toxicity. Unfortunately, the mechanism for cisplatin nephrotoxicity has not been completely elucidated; however, many theories have been developed. Other toxicities include gastrointestinal, myelosuppression, ototoxicity and neurotoxicity. Saline diuresis is currently the most accepted way to prevent cisplatin nephrotoxicity. Research has focused on pharmaceuticals and enzyme/molecular alterations as alternatives to long‐term diuresis. No agents have currently been identified that can protect from all toxicities. Cisplatin has shown activity against osteosarcoma, transitional cell carcinoma, squamous cell carcinoma (SCC), melanoma, mesothelioma, carcinomatosis and germinal cell tumours in the dog. In the cat, cisplatin cannot be utilized because of fulminant pulmonary oedema that occurs at standard doses. Intralesional cisplatin has been utilized in horses for the treatment of SCC and sarcoids. 相似文献
4.
为了探讨黄秋葵嫩果醇提物对顺铂致小鼠急性肾损伤是否具有保护作用,将50只SPF级ICR雄性小鼠随机均分为空白对照组(0.9%生理盐水)、模型组(0.9%生理盐水)、黄秋葵醇提物(HQK)高中低剂量组(400、200、100 mg/kg),分别灌胃给药7 d,除空白对照组,于第7天给药1 h后灌胃给顺铂20 mg/kg。再灌胃给药3 d后,眼球取血,测定血清中尿素氮(BUN)、肌酐(CRE)、超氧化物歧化酶(SOD)、还原型谷胱甘肽(GSH)和丙二醛(MDA)的含量;测定肾脏匀浆中SOD、GSH和MDA含量;并观察苏木精-伊红(HE)病理切片组织病理学变化。结果表明:与模型组比较,HQK高、中剂量组中BUN、CRE含量均降低,肾组织GSH、SOD含量均升高(P0.01,P0.05),HE染色观察HQK高剂量组可显著保护顺铂致肾组织病理损害。黄秋葵醇提取物对CDDP诱导的小鼠急性肾损伤均有一定的保护作用。 相似文献
5.
采用水提醇沉法提取6种真菌中的糖蛋白,通过苯酚—硫酸法、间羟基联苯法、BCA法测定其总糖、酸性糖和蛋白质含量,采用PMP柱前衍生化法和HPGPC法测定其单糖组成及分子量分布,采用顺铂建立受损肾细胞模型,研究6种食用真菌糖蛋白的恢复作用。结果表明,香菇糖蛋白的总糖含量最高,为38.11%,口蘑糖蛋白中蛋白质含量最高,为34.21%,各糖蛋白中酸性糖含量均较低且相差不大;6种食用真菌糖蛋白中均含有甘露糖、葡萄糖和半乳糖,其分子量在500~20 000 u之间,在质量浓度为12.5~50 μg·mL-1时6种多糖对受损肾细胞具有一定的恢复作用。理化性质测定结果表明,这6种食用真菌糖蛋白均含有较高的多糖成分,且均对顺铂诱导的肾细胞损伤具有一定的恢复能力。 相似文献
6.
L. R. Raposo C. Roma‐Rodrigues P. Faísca M. Alves J. Henriques M. C. Carvalheiro M. L. Corvo P. V. Baptista A. J. Pombeiro A. R. Fernandes 《Veterinary and comparative oncology》2017,15(3):952-967
Here we describe the establishment of a new canine mammary tumour (CMT) cell line, FR37‐CMT that does not show dependence on female hormonal signaling to induce tumour xenografts in NOD‐SCID mice. FR37‐CMT cell line has a stellate or fusiform shape, displays the ability to reorganize the collagen matrix, expresses vimentin, CD44 and shows the loss of E‐cadherin which is considered a fundamental event in epithelial to mesenchymal transition (EMT). The up‐regulation of ZEB1, the detection of phosphorylated ERK1/2 and the downregulation of DICER1 and miR‐200c are also in accordance with the mesenchymal characteristics of FR37‐CMT cell line. FR37‐CMT shows a higher resistance to cisplatin (IC50>50 µM) and to doxorubicin (IC50>5.3 µM) compared with other CMT cell lines. These results support the use of FR37‐CMT as a new CMT model that may assist the understanding of the molecular mechanisms underlying EMT, CMT drug resistance, fostering the development of novel therapies targeting CMT. 相似文献
7.
8.
Uncaria species (Gouteng in Chinese) have been used as a plant medicine to treat ailments of cardiovascular and central nervous systems. As the main alkaloid constituent of Uncaria species, isorhynchophylline has drawn extensive attention toward antihypertensive and neuroprotective activities in recent years. Isorhynchophylline mainly acts on cardiovascular and central nervous systems diseases including hypertension, brachycardia, arrhythmia, and sedation, vascular dementia, and amnesia. Isorhynchophylline also has effects on anticoagulation, inhibition vascular smooth muscle cell apoptosis and proliferation, anti-multidrug resistant of lung cells, anti-endotoxemic, and antispasmodic. The active mechanisms are related to modulation on calcium ion channel, protection neural and neuroglial cells against β-amyloid(25-35)-induced neurotoxicity and via inducing autophagy. As a candidate drug of several cardiovascular and central nervous systems diseases, isorhynchophylline will attract scientists to pursue the potential related pharmacological effects and its mechanism with new technologies. But relatively few clinical application of isorhynchophylline has been conducted on its pharmacological activities. It requires more in vivo validations and further investigations of antihypertensive and neuroprotective mechanisms of isorhynchophylline. 相似文献
9.
目的观察吉西他滨联合顺铂和紫杉醇联合顺铂对晚期肺鳞癌的疗效差异。方法 78例病理确诊的Ⅲb~Ⅳ期肺鳞癌患者随机分为GP组和TP组,分别采用吉西他滨联合顺铂、紫杉醇联合顺铂治疗,每组39例。21 d为1个周期,至少接受4个周期化疗,每2个周期通过胸部CT评价疗效。结果 GP组和TP组中位生存期分别为11.6个月和10.1个月,1a生存率分别为53.8%和30.8%,差异有统计学意义（P〈0.05）;临床获益率分别为33.3%和28.2%,疾病控制率分别为79.4%和76.9%,差异无统计学意义（P〉0.05）。结论 GP与TP方案治疗晚期肺鳞癌疗效相当,但GP方案可获得更高的中位生存期和1 a生存率。 相似文献
10.
D. M. Vail H. S. Rodabaugh G. A. Conder J. F. Boucher S. Mathur 《Veterinary and comparative oncology》2007,5(1):38-46
Chemotherapy‐induced nausea and vomiting (CINV) is a common side‐effect of cisplatin therapy. Maropitant (Cerenia?), a novel neurokinin‐1 receptor antagonist, was evaluated for prevention and treatment of cisplatin‐induced emesis in tumour‐bearing dogs. Dogs (n= 122) were randomly allocated to three treatment groups: T01, placebo before and after cisplatin; T02, placebo before and maropitant after cisplatin; or T03, maropitant before and placebo after cisplatin. Maropitant treatment (T02) following a cisplatin‐induced‐emetic event resulted in significantly fewer subsequent emetic events (P= 0.0005) than in placebo‐treated dogs (T01). In placebo‐treated (T01) dogs, 56.4% were withdrawn from the study because of treatment failure compared with 5.3% in group T02. When maropitant was administered prior to cisplatin treatment (T03) in a prevention regime, 94.9% did not vomit compared with only 4.9% of placebo‐treated dogs, and significantly fewer emetic events (P < 0.0001) were observed in those dogs that did vomit. In summary, maropitant was safe and highly effective in reducing or completely preventing cisplatin‐induced emesis. 相似文献